alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
United States Securities & Exchange Commission EDGAR Filing


Exhibit 10.1










Summary of

Accelerated Vesting of Certain Options










On August 11, 2005, our Compensation Committee accelerated the vesting of 220,000 out-of-the-money stock options exercisable at $40.39 per share and 243,975 out-of-the-money stock options exercisable at $44.43 per share. 




The options were issued to key PharmaNet, Inc. executives in December 2004. 103,800 of the stock options exercisable at $44.43 per share are held by Mr. Jeffrey P. McMullen, who is the president and chief executive officer of PharmaNet. Mr. McMullen is also one of our executive officers and serves on our board of directors. One half of the options described above were to have vested in 2006 and the remainder were to have vested in 2007, subject to continued employment on each vesting date. In addition, each executive has agreed not to sell any shares of common stock issued as the result of options exercised prior to the original applicable vesting dates except to the extent necessary to pay SFBC the exercise price.




The primary purpose of the accelerated vesting was to eliminate future compensation expense the Company would otherwise recognize in its consolidated statement of operations with respect to these accelerated options upon the adoption of Financial Accounting Standards Board Statement of Financial Accounting Standards No. 123 (Revised 2004), Share-Based Payment.




The acceleration of the vesting of these options did not result in a charge based on accounting principles generally accepted in the United States.
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                           6,536
<INT-BEARING-DEPOSITS>                           5,503
<FED-FUNDS-SOLD>                                 1,420
<TRADING-ASSETS>                                12,364
<INVESTMENTS-HELD-FOR-SALE>                     43,517
<INVESTMENTS-CARRYING>                          14,013
<INVESTMENTS-MARKET>                            14,209
<LOANS>                                        226,298
<ALLOWANCE>                                      5,573
<TOTAL-ASSETS>                                 323,020
<DEPOSITS>                                     281,349
<SHORT-TERM>                                    13,000
<LIABILITIES-OTHER>                              6,933
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           845
<OTHER-SE>                                      20,893
<TOTAL-LIABILITIES-AND-EQUITY>                 323,020
<INTEREST-LOAN>                                  9,343
<INTEREST-INVEST>                                2,292
<INTEREST-OTHER>                                   180
<INTEREST-TOTAL>                                11,815
<INTEREST-DEPOSIT>                               6,261
<INTEREST-EXPENSE>                               6,355
<INTEREST-INCOME-NET>                            5,460
<LOAN-LOSSES>                                        0
<SECURITIES-GAINS>                                 (65)
<EXPENSE-OTHER>                                  4,739
<INCOME-PRETAX>                                  2,111
<INCOME-PRE-EXTRAORDINARY>                       1,296
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,296
<EPS-PRIMARY>                                      .15
<EPS-DILUTED>                                      .15
<YIELD-ACTUAL>                                    7.93
<LOANS-NON>                                      4,109
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                 4,847
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 5,613
<CHARGE-OFFS>                                       58
<RECOVERIES>                                        18
<ALLOWANCE-CLOSE>                                5,573
<ALLOWANCE-DOMESTIC>                             5,573
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
___________

United States Department of Com

National Institute of Standards and Technolo

Certificate of Metrological Traceability For: 

Maine 

This laboratory has demonstrated evidence of an unbroken chain of metrological traceability of its standards to the international system of units (SI), documented measurement uncertainties, uses documented measurement procedures, successfully 

completed training and proficiency tests, documented calibration intervals, submitted a quality management system, anddemonstrated suitable measurement assurance for the Scope listed on this certificate. The Office of Weights and Measures Program assesses laboratories to NIST Handbook 143 - Program Handbook for State Weights and Measures Laboratories and ISO/IEC 17025:2017. 

Scope 

Mass Echelon II 30 kg to 1 mg 

1000 lb to 0.001 lb 8 oz to 0.03125 oz Mass Echelon III 

30 kg to 1 mg 

1000 lb to 0.001 lb 

8 oz to 0.03125 oz 

Weight Carts 7000 lb to 2000 lb Wheel Load Weighers 20 000 lb to 5000 lb 

Volume Gravimetric, I 

200 L to 5 L 100 gal to 5 gal 

Volume Transfer, II 5000 L to 19 L 1500 gal to 5 gal Volume Transfer, II LPG 300 gal to 20 gal Length, Special Shellfish 6 in to 1 in 

Katrice LippNIST Office Effective Date

(Rev.: September 2021)
EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of GOL LINHAS AÉREAS INTELIGENTES S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2016, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Paulo Sergio Kakinoff, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the U.S. Sarbanes Oxley Act of 2002, that to the best of my knowledge: (i) the Report fully complies with the requirements of section 13(a) or 15(d) of the U.S. Securities Exchange Act of 1934; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: May 1, 2017 By:               /s/PauloSergio KakinoffName:Paulo Sergio KakinoffTitle:Chief Executive Officer
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

JUDGMENT RENDERED FEBRUARY 28, 2020

NO. 03-19-00741-CV

E. E. and C. C., Appellants

v.

Texas Department of Family and Protective Services, Appellee

APPEAL FROM THE 421ST DISTRICT COURT OF CALDWELL COUNTY

BEFORE CHIEF JUSTICE ROSE, JUSTICES TRIANA AND SMITH

AFFIRMED IN PART; REVERSED AND REMANDED IN PART --

OPINION BY JUSTICE TRIANA

This is an appeal from the order signed by the trial court on October 11, 2019. Having reviewed 

the record and the parties’ arguments, the Court holds that there was reversible error in the 

court’s order. Therefore, the Court reverses the trial court’s order terminating the mother’s 

parental rights and remands that portion of the cause to the district court for further proceedings

consistent with this opinion. We instruct the district court to commence any new trial on remand

no later than 180 days after the mandate is issued by this Court. We otherwise affirm the district

court’s order of termination. Because Appellants are indigent and unable to pay costs, no 

adjudication of costs is made.
FIRST LICENSE AGREEMENT
AMENDMENT





THE FIRST LICENSE AGREEMENT AMENDMENT
is made as of April 20, 2010 by ROCHESTER BIOVENTURE CENTER, INC., ("Licensor"),
and SENSIVIDA MEDICAL TECHNOLOGIES, INC. ("Licensee").





WITNESSETH:





WHEREAS, Licensor has provided to
Licensee for use of Room 164 located at 77 Ridgeland Road, Henrietta, New York
14623 pursuant to the terms of a certain LICENSEE AGREEMENT, dated December 15,
2008 by and between Licensor and Licensee (the "License Agreement");
and





WHEREAS, Licensor and Licensee desire
to amend the terms of the License Agreement to include Office 101D as part of
the Premises pursuant to the terms of this First License Agreement
Amendment;





NOW, THEREFORE, in consideration of Ten
Dollars ($10.00) in hand paid and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto do
hereby agree as follows:




1.           The
Premises is hereby amended to be Room 164 and Office 101D located at 77
Ridgeland Road, Henrietta, NY 14623.




2.           The
annual License Fee for Room 164 and Office 101D shall be $13,200.00, to be paid
in monthly installments of $1,100.00.




3.           Licensor
agrees that Licensee has the option to extend the term of the License to
month-to-month tenancy subject to all covenants, conditions and terms of the
current License Agreement.  The License shall run month-to-month
effective May 1, 2010 until either party notifies the other of its intention to
terminate the License, and in such event, the License will expire on the last
day of the next month after delivery of said notice.




4.           Each
party warrants and represents to the other party hereto that it has not dealt
with any brokers in connection with this First License Agreement
Amendment.  Each party hereby indemnifies and holds the other party
harmless from any and all loss and expense arising out of or in connection with
any breach of the foregoing warranty and representation.  The
provisions of this paragraph 2 shall survive the expiration or earlier
termination of the Agreement.




5.           This
First License Agreement Amendment shall commence on May 1, 2010 and will
terminate as provided in paragraph 3 above, or on February 13, 2013, whichever
occurs earlier.




6.           All
capitalized terms used herein and not otherwise defined shall have the meanings
ascribed thereto in the License Agreement.  Except as herein expressly
amended, the License Agreement shall remain unchanged and is hereby ratified
confirmed and approved.




IN
WITNESS WHEREOF Licensor and Licensee have executed this License Agreement
Amendment as of the day and year first above written.





LICENSOR:
                
                LICENSEE:ROCHESTER
      BIOVENTURE CENTER, INC.
                
                SENSIVIDA
      MEDICAL TECHNOLOGIES, INC.By:
                /s/ James S. Senall
                
                By:
                /s/ Jose MirName:   James
      S. Senall
                
                Name:  Jose
      MirTitle:     President
                
                Title:    President
      and CEO
```

[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4227 Engrossed in House (EH)]

  2d Session

                               H. R. 4227

_______________________________________________________________________

                                 AN ACT

   To amend the Internal Revenue Code of 1986 to extend to 2005 the 
alternative minimum tax relief available in 2003 and 2004 and to index 
                       such relief for inflation.
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
108th CONGRESS
  2d Session
                                H. R. 4227

_______________________________________________________________________

                                 AN ACT

 
   To amend the Internal Revenue Code of 1986 to extend to 2005 the 
alternative minimum tax relief available in 2003 and 2004 and to index 
                       such relief for inflation.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited at the ``Middle-Class Alternative Minimum Tax 
Relief Act of 2004''.

SEC. 2. EXTENSION OF ALTERNATIVE MINIMUM TAX RELIEF TO 2005.

    (a) In General.--Subparagraphs (A) and (B) of section 55(d)(1) of 
the Internal Revenue Code of 1986 are each amended by striking ``and 
2004'' and inserting ``, 2004, and 2005''.
    (b) Inflation Adjustment.--Subsection (d) of section 55 of such 
Code is amended by inserting after paragraph (3) the following new 
paragraph:
            ``(4) Inflation adjustment.--
                    ``(A) In general.--In the case of any taxable year 
                beginning in calendar year 2005, the $58,000 amount 
                contained in paragraph (1)(A) and the $40,250 amount 
                contained in paragraph (1)(B) shall each be increased 
                by an amount equal to--
                            ``(i) such dollar amount, multiplied by
                            ``(ii) the cost-of-living adjustment 
                        determined under section 1(f)(3) for the 
                        calendar year in which the taxable year begins, 
                        determined by substituting `2003' for `1992' in 
                        subparagraph (B) thereof.
                    ``(B) Rounding.--Any increase determined under 
                subparagraph (A) which is not a multiple of $50 shall 
                be rounded to the next lowest multiple of $50.''.
    (c) Effective Date.--The amendments made by this section shall 
apply to taxable years beginning after December 31, 2004.

            Passed the House of Representatives May 5, 2004.

            Attest:

                                                                 Clerk.
```
#### J. T. Curry *v.*J. H. Privett.

Equity — Coming into Equity with Clean Hands.

A court of equity will not grant relief to one wiio does not come into equity witlh. clean hands.

APPEAL FROM ADAIR CIRCUIT COURT.

January 21, 1873.

Opinion by

Judge Pryor:

The appellee has made so many conflicting statements under oath in regard to the matters in controversy as compels the chancellor to deny him' the relief sought.

His whole object, as he himself avows, in selling his land to the appellant was to defraud his creditors, and in order to accomplish this purpose, when prosecuting his suit in bankruptcy, has more than once sworn that he had no interest in the land now the subject of this litigation.

*373
      *Garnett,*James, *for appellant.*

*Winfrey & Winfrey, for appellee.*

After his discharge in bankruptcy he institutes the present action, alleging that the bond for title was assigned to the appellant as a mere indemnity for borrowed money, and during its progress his statements under oath are so inconsistent as evidences a willingness on his part to make any assertion necessary to the successful prosecution of his action.

The chancellor will hear no such complaint. The court below, by its judgment, should have the parties occupy the same position towards each other with reference to the property, which they did prior to the institution of appellee’s action.

The judgment of the court below is reversed and cause remanded with directions to dismiss the case at appellant’s costs.
Exhibit 12.1
Certification by the Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Steve Turcotte, Chief Executive Officer of Global
Mainframe Corp. (the "Company"), certify that:
1. I have reviewed this annual report on Form 20-F of the Company;
2. Based on my knowledge, this report does not contain any
 untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in
light of the circumstances under which such statements were
 made, not misleading with respect to the period covered by
this report;
3. Based on my knowledge, the financial statements, and other
 financial information included in this report, fairly present
 in all material respects the financial condition, results of
 operations and cash flows of the Company as of, and for, the
periods presented in this report;
4. The Company's other certifying officer(s) and I are responsible
 for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
 Company and we have:
(a) Designed such disclosure controls and procedures, or caused such
 disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the Company, including
its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report
is being prepared;
(b) Evaluated the effectiveness of the Company's disclosure controls
 and procedures and presented in this report our conclusions about
the effectiveness of the controls and procedures, as of the end of
the period covered by this report based on such evaluation; and
(c) Disclosed in this report any change in the Company's internal
control over financial reporting that occurred during the period covered
by this annual report that has materially affected, or is reasonably
likely to materially affect, the Company's internal control over financial
 reporting; and
5. The Company's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
 reporting, to the Company's auditors and the audit committee of
Company's board of directors (or persons performing the equivalent function):
(a) All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably
 likely to adversely affect the Company's ability to record, process,
summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the Company's internal control
 over financial reporting.
Date: November 13, 2007

By:	 	/s/ Steve Turcotte
Name:	 	Steve Turcotte
Title:	 	Chief Executive Officer
[Federal Register Volume 79, Number 230 (Monday, December 1, 2014)]
[Notices]
[Page 71101]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-28371]


=======================================================================
-----------------------------------------------------------------------

FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION


Sunshine Act Meeting

November 26, 2014.

TIME AND DATE: 10:00 a.m., Thursday, December 11, 2014.

PLACE:  The Richard V. Backley Hearing Room, Room 511N, 1331 
Pennsylvania Avenue NW., Washington, DC 20004 (enter from F Street 
entrance).

STATUS:  Open.

MATTERS TO BE CONSIDERED:  The Commission will consider and act upon 
the following in open session: Secretary of Labor v. Excel Mining, LLC, 
Docket No. KENT 2009-1368. (Issues include whether the Administrative 
Law Judge erred by affirming a ``significant and substantial'' 
designation and an ``unwarrantable failure to comply'' designation.) 
Any person attending this meeting who requires special accessibility 
features and/or auxiliary aids, such as sign language interpreters, 
must inform the Commission in advance of those needs. Subject to 29 CFR 
2706.150(a)(3) and 2706.160(d).

CONTACT PERSON FOR MORE INFORMATION:  Emogene Johnson (202) 434-9935/
(202) 708-9300 for TDD Relay/1-800-877-8339 for toll-free.

Sarah L. Stewart,
Deputy General Counsel.
[FR Doc. 2014-28371 Filed 11-26-14; 4:15 pm]
BILLING CODE 6735-01-P
7/18/2018

Yegor Vekhov

Instructions for Prepping an Orange Cryostat 

Pumping Vacuum Jacket 

1. Connect a turbo pump to the vacuum valve and pump down to the mid 10-5 torr range. If 

the cryostat has recently been in use and not experienced any problems, you can skip this 

step. 

Purge the Helium Reservoir and Sample Well 

If possible, the sample stick should be in the cryostat before this step is begun. 

1. Connect the rough pump to the helium exhaust port, start the pump and open the red valve 

and the warm valve. 

2. Turn the blue 3-way valve down. This makes the reservoir and sample well common and 

allows you to pump both through the helium exhaust port. 

3. Pump the volume down to 3-4mbar, then close the valve to the pump and open the valve 

to the helium gas. 

4. Do it three times, ending with 3-5 psi (above the atmospheric pressure) of helium gas in 

the cryostat. 

5. Close the blue 3-way valve (horizontal), the red exhaust valve, and the warm valve. 

Disconnect the rough pump. 

Fill with Cryogens 

1. It takes about 20L of Helium to fill a standard (short) 50 or 70 mm cryostat and about 30-

35L to fill the larger models (DCS, MACS, HFBS, ICE). 

2. Start by filling with liquid helium through the helium fill port. Also make sure the helium 

exhaust port (red valve) is opened. Open the cold and warm valves slightly. 

3. Once the helium is going, fill the nitrogen jacket through any of the three ports. 

4. Helium is collecting in the cryostat once a thick white plume is visible at the exhaust port. 

The helium reservoir is full when this plume suddenly becomes much more intense. 

5. After you have put away the transfer line, close the helium fill port and the helium exhaust 

port on the cryostat. 

Cooling Down 

1. Connect the sensors to a temperature controller. The cryostat and sample stick sensors are 

Cernox ones (some old sensors can be Silicon Diode type). The calibration curve for the 

cryostat and sample stick sensors are written on the top side of the cryostat and on the top 

flange of the stick, correspondently. 

2. To cool down to 4.2 K relatively quickly, use the cold and warm valves. The cold valve 

should be opened about a half turn, while the warm valve should be opened several turns. 

Watch how quickly the temperature falls and vary the valve settings to cool as quickly as 

possible. 

3. To cool below 4.2 K, or to cool very quickly, use one of the large roughing pumps 

(Kashiyama NeoDry 30E is preferred pump). Connect it to the annulus, close the warm 

valve, and either close the cold valve or leave it very slightly open. Then start the pump.